Compare · PACB vs WAT
PACB vs WAT
Side-by-side comparison of Pacific Biosciences of California Inc. (PACB) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PACB and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $30.15B, about 60.7x PACB ($496.8M).
- Over the past year, PACB is up 40.4% and WAT is down 12.4% - PACB leads by 52.7 points.
- WAT has been more active in the news (8 items in the past 4 weeks vs 6 for PACB).
- WAT has more recent analyst coverage (25 ratings vs 24 for PACB).
- Company
- Pacific Biosciences of California Inc.
- Waters Corporation
- Price
- $1.60+0.63%
- $307.03-0.71%
- Market cap
- $496.8M
- $30.15B
- 1M return
- +19.40%
- +2.37%
- 1Y return
- +40.35%
- -12.39%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- 1995
- News (4w)
- 6
- 8
- Recent ratings
- 24
- 25
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest PACB
- SEC Form DEFA14A filed by Pacific Biosciences of California Inc.
- SEC Form DEF 14A filed by Pacific Biosciences of California Inc.
- PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
- PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
- PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples
- SEC Form 4 filed by Gibson Christopher
- SEC Form 4 filed by Gibson James R Ii
- Amendment: SEC Form SCHEDULE 13G/A filed by Pacific Biosciences of California Inc.
- Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
Latest WAT
- Amendment: SEC Form SCHEDULE 13G/A filed by Waters Corporation
- Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
- Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
- SEC Form DEFA14A filed by Waters Corporation
- SEC Form DEF 14A filed by Waters Corporation
- Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
- SEC Form 4 filed by Bennett Jianqing
- Waters upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Jiang Wei
- SEC Form 4 filed by Knight Heather